In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics (BOLD), with a price target of $45.00. The company’s shares closed last Monday at $27.84.
According to TipRanks.com, Yang is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.7% and a 32.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Audentes Therapeutics with a $39.75 average price target, representing a 42.6% upside. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $55.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.65 and a one-year low of $17.95. Currently, Audentes Therapeutics has an average volume of 412.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
